Properties (62)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
monoclonal antibody
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:chemicalFormula |
C6424H9924N1716O1980S44
|
| gptkbp:clinicalTrials |
gptkb:IMvigor211
combination therapy Phase III ASCO guidelines monotherapy Cohort 1 of the IMvigor010 trial IMvigor130 KEYNOTE-355 NCCN_guidelines |
| gptkbp:contraindication |
hepatitis
pneumonitis active autoimmune disease colitis endocrinopathies concurrent immunosuppressive therapy history of severe hypersensitivity nephritis |
| gptkbp:developedBy |
gptkb:Genentech
|
| gptkbp:dosageForm |
solution for infusion
|
| gptkbp:drugInterdiction |
enhances T-cell activation
half-life of approximately 27 days increases immune response against tumors inhibits_PD-L1_binding_to_PD-1 |
| gptkbp:formulation |
lyophilized powder
|
| https://www.w3.org/2000/01/rdf-schema#label |
Atezolizumab
|
| gptkbp:is_monitored_by |
liver function tests
complete blood count thyroid function tests renal function tests |
| gptkbp:issuedBy |
intravenous infusion
|
| gptkbp:lastProduced |
2016
|
| gptkbp:launchSite |
vein
|
| gptkbp:marketedAs |
gptkb:Tecentriq
gptkb:Australia gptkb:Canada gptkb:European_Union gptkb:Japan gptkb:United_States |
| gptkbp:patentStatus |
patented
|
| gptkbp:provides |
non-small cell lung cancer
urothelial carcinoma triple-negative breast cancer |
| gptkbp:researchAreas |
clinical trials
|
| gptkbp:route |
intravenous
|
| gptkbp:sideEffect |
fatigue
nausea diarrhea rash immune-related adverse events |
| gptkbp:storage |
2 to 8 degrees Celsius
|
| gptkbp:targets |
gptkb:PD-L1
lung cancer breast cancer bladder cancer |
| gptkbp:triggerType |
immune checkpoint inhibitor
|
| gptkbp:usedFor |
treatment of cancer
|
| gptkbp:variant |
chemotherapy
targeted therapy |
| gptkbp:weight |
146 kDa
|